Osteoporosis
428 results
201 - 300
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women
USPSTF 2025 recommends screening to prevent osteoporotic fractures in women 65 years and older (B recommendation)- Denosumab reduces fracture risk better than placebo (FREEDOM)
- Lasofoxifene has disease-specific benefits, but no change in all-cause mortality
- Abaloparatide reduces the risk of osteoporotic fractures in postmenopausal women
- USPSTF 2018 recommends screening to prevent osteoporotic fractures in women 65 years and older (B recommendation)
- Denosumab no better than bisphosphonates at preventing fracture, and the cost is much higher
- Most women quickly stop taking bisphosphonates
Pharmacological glucocorticoid treatment - BMD screening every 15 years for low-risk women
- Reduced all-cause mortality associated with post-fracture bisphosphonate treatment
- Cushing's syndrome
- Health monitoring in the elderly
- Bisphosphonates decrease vertebral fractures but not clinically important fractures in men
- Calcium and vitamin D for increasing bone mineral density in premenopausal women
- Vitamin D = placebo for preventing cognitive decline in African-American women with low vitamin D levels
- Bone anabolic treatments reduce fractures to a greater extent than bisphosphonates in women at high risk
- Menopausal symptoms and hormone therapy
- Bisphosphonate use in children with cerebral palsy
- Vitamin D supplementation: good for bones and fall prevention, but little else
- Polymyalgia rheumatica
- Klinefelter’s syndrome
- Vitamin D and vitamin D analogues for preventing fractures in post‐menopausal women and older men
- Professional interventions for general practitioners on the management of musculoskeletal conditions
- Hypocalcaemia, hypoparathyroidism and vitamin D deficiency
- Glucocorticosteroids for primary biliary cirrhosis
- Male hypogonadism and hormone replacement
- Curable causes of cognitive challenges and memory disease
- Parathyroid hormone prevents recurrent fractures
- Corticosteroids for maintenance of remission in Crohn's disease
- Benign paroxysmal positional vertigo (BPPV)
- Email for clinical communication between healthcare professionals
- Giant cell (temporal) arteritis
- Alendronate associated with reduced risk of hip fracture in older adults taking medium- to high-dose steroids
- Interventions for the treatment of decreased bone mineral density associated with HIV infection: Cochrane systematic review
- Interventions for improving the appropriate use of imaging in people with musculoskeletal conditions
- Oral corticosteroids for stable chronic obstructive pulmonary disease
- Zoledronic acid reduces asymptomatic fractures but not clinical ones in men
- Vitamins for epilepsy
- Anaesthesia for treating distal radial fracture in adults
- Parathyroidectomy for adults with primary hyperparathyroidism
- Thiazide diuretics and the risk of hip fracture: Cochrane systematic review
- Calcium supplementation for the management of primary hypertension in adults
- Short-bowel syndrome
- Effects of continuing or stopping alendronate after 5 years of treatment
- Zoledronate 5 mg every 18 months reduces fragility fractures in women over 65 with osteopenia (NNT = 15 over 6 years)
- Calcium supplementation on bone loss in postmenopausal women: Cochrane systematic review
- Falls of the elderly
- USPSTF: Uncertain benefit of vitamin D and calcium for fracture prevention
- Dryness of the mouth
- Gonadotrophin‐releasing hormone analogues for endometriosis: bone mineral density
- Coeliac disease
- Zoledronate given twice 5 years apart to women with normal bone density or osteopenia reduces fracture risk (NNT = 9 over 10 years)
- Cystic fibrosis (CF)
- Primary care follow-up of thyroid cancer after treatment
- Hyperthyroidism
- Hypercalcaemia and hyperparathyroidism
- Vitamins
- Percutaneous vertebroplasty for osteoporotic vertebral compression fracture
- Gonadotropin‐releasing hormone (GnRH) analogues for premenstrual syndrome (PMS)
- Corticosteroids for the treatment of Duchenne muscular dystrophy
- Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure in premenopausal women
- Systemic lupus erythematosus (SLE)
- Primary biliary cholangitis
- Pituitary tumours
- Gastric cancer
- Automated telephone communication systems for preventive healthcare and management of long-term conditions: Cochrane systematic review
- Interventions for managing medication‐related osteonecrosis of the jaw
- Long‐term hormone therapy for perimenopausal and postmenopausal women
- Fractures of the ribs and pelvis
- Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease: Cochrane systematic review
- Autoimmune hepatitis
- Interventions for decreased bone mineral density associated with HIV infection
- Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women: Cochrane systematic review
- Exercise alone and various combinations of interventions reduces the risk of injurious falls in older adults
- Exemestane reduces breast cancer risk in high-risk postmenopausal women
- Nutritional interventions for survivors of childhood cancer
- Corticosteroids for the long-term treatment in multiple sclerosis